New drug etrinabdione tested for leg artery disease
NCT ID NCT06774040
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase IIa trial tests the safety and tolerability of a new drug called etrinabdione in 30 adults with peripheral arterial disease (PAD). Participants take the drug twice daily for 12 months, starting with a low dose and possibly moving to a higher dose if safe. Researchers will also check if the drug improves blood flow and walking ability.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
etrinabdione
What this could lead to
If successful, this could point toward a new treatment option for peripheral arterial disease that improves blood flow and walking ability.
What could go wrong
This is an early, small Phase IIa trial with only 30 participants. It primarily tests safety, not effectiveness, and the higher dose may be stopped if safety concerns arise.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL ARTERIAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital Universitario Reina Sofía
Córdoba, 14014, Spain